...We Welcome You To The Resverlogix HUB In The AGORACOM COMMUNITY!

** Apabetalone (RVX-208) Currently Being Tested in a Phase 3 BETonMACE Cardiovascular Outcomes Trial ** Trial is Fully Enrolled and Top-Line Results Expected Q1 2019

Free
Message: Lilly to Discontinue Development of Evacetrapib

Looks like he is really sticking the knife in. "Lilly's Evacetrapib best ever in biological effect" "Very unlikely other CETP inhibitors will work". I bet Merck is pleased with those comments!

Share
New Message
Please login to post a reply